Renal Clinical Trials

770 recruitingLast updated: May 13, 2026

There are 770 actively recruiting renal clinical trials across 80 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Renal Trials at a Glance

770 actively recruiting trials for renal are listed on ClinicalTrialsFinder across 6 cities in 80 countries. The largest study group is Not Applicable with 209 trials, with the heaviest enrollment activity in Houston, Boston, and New York. Lead sponsors running renal studies include National Cancer Institute (NCI), Peking University First Hospital, and M.D. Anderson Cancer Center.

Treatments under study

About Renal Clinical Trials

Looking for clinical trials for Renal? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 770 trials

Recruiting
Phase 1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

HealthyRenal Impairment
Pfizer28 enrolled4 locationsNCT07315360
Recruiting
Phase 1

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Adrenocortical Carcinoma (ACC)Carcinoma, AdrenocorticalCarcinoma, Adrenal Cortical+2 more
National Cancer Institute (NCI)32 enrolled1 locationNCT06487481
Recruiting

Stone and Laser Therapies Post-Market Study (SALT)

Benign Prostate Hypertrophy(BPH)Ureteral Stones, Kidney StonesCalculi, Urinary+2 more
Boston Scientific Corporation238 enrolled5 locationsNCT06982235
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled31 locationsNCT06465069
Recruiting

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

HypertensionCardiovascular DiseaseAdrenal Gland Neoplasm+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,150 enrolled1 locationNCT03374215
Recruiting
Phase 2Phase 3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled494 locationsNCT05987241
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled108 locationsNCT07227402
Recruiting
Phase 3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Carcinoma, Renal CellVon Hippel-Lindau Disease
Merck Sharp & Dohme LLC450 enrolled11 locationsNCT07405164
Recruiting
Phase 1Phase 2

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC140 enrolled28 locationsNCT07049926
Recruiting
Not Applicable

Time-restricted Eating in Patients With Moderate Chronic Kidney Disease and Albuminuria

Renal Insufficiency, Chronic
de Seigneux Sophie50 enrolled1 locationNCT06618859
Recruiting
Phase 3

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Carcinoma, Renal Cell
Merck Sharp & Dohme LLC758 enrolled7 locationsNCT07489495
Recruiting
Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Renal Cell Carcinoma (RCC)Clear Cell Renal Cell CarcinomaStage II Renal Pelvis Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,040 enrolled410 locationsNCT06661720
Recruiting
Not Applicable

AI-Guided Relaxation for Hemodialysis Anxiety

AnxietyMaintenance HemodialysisStress, Psychological+2 more
Alexandria University60 enrolled2 locationsNCT07522944
Recruiting
Phase 2

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Metastatic MelanomaMetastatic Renal Cell CarcinomaAdvanced Locoregional Melanoma+1 more
National Cancer Institute (NCI)78 enrolled1 locationNCT05155033
Recruiting
Phase 2

CD70-targeted immunoPET Imaging of Malignant Cancers

LymphomaRenal CancerMantle Cell Lymphoma+4 more
RenJi Hospital300 enrolled1 locationNCT06852638
Recruiting
Phase 1

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+3 more
City of Hope Medical Center33 enrolled2 locationsNCT07128680
Recruiting
Phase 2

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Stage IV Bladder Cancer AJCC v7Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial Carcinoma+3 more
Mayo Clinic70 enrolled1 locationNCT07087860
Recruiting

Natural History Study of Patients With Excess Androgen

Congenital Adrenal Hyperplasia (CAH)Familial Male-Limited Precocious Puberty (FMPP)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)3,000 enrolled2 locationsNCT00250159
Recruiting
Phase 1Phase 2

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Kidney TransplantToleranceRenal Transplant Rejection
Jeffrey Veale, MD15 enrolled1 locationNCT03707262